Experience with rifabutin replacing rifampin in the treatment of tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 11, 2011, Pages 1485-1489

  Horne, David J ^a   Spitters, C ^a,b   Narita, M ^a,b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b PUBLIC HEALTH SEATTLE AND KING COUNTY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Adverse effects; Rifabutin; Rifampin; Tuberculosis treatment

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN;

ABDOMINAL DISCOMFORT; ADULT; ADVERSE OUTCOME; ANGIONEUROTIC EDEMA; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; CYTOPENIA; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION RISK; LIP DISEASE; LIVER INJURY; MAJOR CLINICAL STUDY; MALAISE; MALE; MUSCULOSKELETAL DISEASE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PRURITUS; RASH; RISK ASSESSMENT; RISK FACTOR; SKIN DISEASE; TONGUE DISEASE; TREATMENT OUTCOME; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VOMITING;

ADULT; AGED; ANTIBIOTICS, ANTITUBERCULAR; CHI-SQUARE DISTRIBUTION; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RIFABUTIN; RIFAMPIN; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS; WASHINGTON;

EID: 80054006532     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0068     Document Type: Article

References (22)

1. Iseman M D. A clinician's guide to tuberculosis. Philadelphia, PA, USA: Lippincott Williams & Wilkins, 2000.
2. Treatment of tuberculosis. MMWR Recomm Rep 2003; 52 (RR-11): 1-77.
3. Martinez E, Collazos J, Mayo J. Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions. Medicine 1999 (Baltimore); 78: 361-369.
4. Aristoff P A, Garcia G A, Kirchhoff P D, Hollis Showalter H D. Rifamycins - obstacles and opportunities. Tuberculosis 2010 (Edinb); 90: 94-118.
5. Grassi C, Peona V. Use of rifabutin in the treatment of pulmonary tuberculosis. Clin Infect Dis 1996; 22 (Suppl 1): S50-S54. (Pubitemid 26256458)
6. Narita M, Stambaugh J J, Hollender E S, Jones D, Pitchenik A E, Ashkin D. Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis. Clin Infect Dis 2000; 30: 779-783.
7. Davies G, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst Rev 2007(4): CD005159.
8. Gonzalez-Montaner L J, Natal S, Yongchaiyud P, Olliaro P. R ifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Rifabutin Study Group. Tubercle Lung Dis 1994; 75: 341-347. (Pubitemid 24336530)
9. McGregor M M, Olliaro P, Wolmarans L, et al. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med 1996; 154: 1462-1467. (Pubitemid 26391198)
10. Schwander S, Rüsch-Gerdes S, Mateega A, et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Tubercle Lung Dis 1995; 76: 210-218.
11. Tattevin P, Revest M, Dupont M, Arvieux C, Michelet C. A regimen containing rifabutin for the treatment of tuberculosis in patients intolerant to rifampin. Clin Infect Dis 2003; 36: 127-128. (Pubitemid 36099112)
12. Mancini P, Pasqua F, Mazzei L, Olliaro P. Rifabutin treatment for tuberculosis patients with liver function abnormalities. J Antimicrob Chemother 1992; 30: 242.
13. Centers for Disease Control and Prevention. Managing drug interactions in the treatment of HIV-related tuberculosis [online]. Atlanta, GA, USA: CDC, 2007. http://www.cdc.gov/tb/ TB-HIV-Drugs/default.htm Accessed July 2011.
14. Tedla Z, Nyirenda S, Peeler C, et al. Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in HIV-infected adults in Botswana. Am J Respir Crit Care Med 2010; 182: 278-285.
15. Marra F, Marra C A, Bruchet N, et al. Adverse drug reactions associated with first-line anti-tuberculosis drug regimens. Int J Tuberc Lung Dis 2007; 11: 868-875. (Pubitemid 47227617)
16. Hosmer D W, Lemeshow S. Applied logistic regression. 2nd ed. New York, NY, USA: Wiley, 2000.
17. Onyebujoh P C, Ribeiro I, Whalen C C. Treatment options for HIV-associated tuberculosis. J Infect Dis 2007; 196 (Suppl 1): S35-S45. (Pubitemid 47206083)
18. Weiner M, Benator D, Burman W, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005; 40: 1481-1491. (Pubitemid 40628637)
19. Burman W, Benator D, Vernon A, et al. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 2006; 173: 350-356. (Pubitemid 43209091)
20. Li J, Munsiff S S, Driver C R, Sackoff J. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clin Infect Dis 2005; 41: 83-91. (Pubitemid 40863749)
21. Dossing M, Wilcke J T, Askgaard D S, Nybo B. Liver injury during antituberculosis treatment: an 11-year study. Tubercle Lung Dis 1996; 77: 335-340. (Pubitemid 26258538)
22. Sharma S K, Singla R, Sarda P, et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis 2010; 50: 833-839.